- World Pharma News Home » Corporate » Nycomed creates a leading specialty pharmaceutical player in dermatology
(a free service delivered by FeedBurner)
Nycomed successfully completed the acquisition of BradleyPharmaceuticals, a company focused on niche therapeutic markets in the United States. Bradley will be integrated into the US specialty business Nycomed US. The acquisition makes Nycomed US a leader in the US dermatology market, with combined annualised dermatology sales of $450 million. In addition, the combined specialty sales force now places Nycomed US among the top five in sales forces selling prescription therapeutics in the US dermatology market.
Nycomed US will expand the line of dermatological products currently offered through its PharmaDerm Division, thereby increasing market coverage and driving future growth.
Discuss Add this link to... Bury
Nycomed US will expand the line of dermatological products currently offered through its PharmaDerm Division, thereby increasing market coverage and driving future growth.
Discuss Add this link to... Bury
Comments